<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423603</url>
  </required_header>
  <id_info>
    <org_study_id>009246QM</org_study_id>
    <secondary_id>2013-001521-43</secondary_id>
    <nct_id>NCT02423603</nct_id>
  </id_info>
  <brief_title>PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer</brief_title>
  <acronym>PAKT</acronym>
  <official_title>A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (PAKT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PAKT was an investigator-led, placebo-controlled, randomized phase II trial performed in 42
      academic medical centers in the United Kindom, South Korea, France, Hungary, Romania, and
      Georgia. Patients were randomly assigned (1:1) to receive paclitaxel plus capivasertib or
      paclitaxel plus placebo. Stratification was by number of metastatic sites (&lt; 3 v ≥ 3) and
      interval from the end of prior adjuvant or neoadjuvant chemotherapy (≤ 12 v &gt; 12 months v no
      prior chemotherapy).

      Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over
      approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg
      or placebo was administered orally twice per day on an intermittent weekly dosing schedule,
      with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle. All treatments
      were continued until disease progression, development of unacceptable toxicity, or withdrawal
      of consent. If paclitaxel treatment was discontinued before disease progression, patients
      could continue to receive capivasertib or placebo alone. In case of adverse events (AEs),
      capivasertib or placebo could be reduced to 320 mg twice per day and subsequently to 240 mg
      twice per day. Capivasertib or placebo could be interrupted for up to 4 weeks for toxicity.

      Tumor assessments included computed tomography scanning or magnetic resonance imaging of the
      chest, abdomen, and pelvis at baseline, every 8 weeks during treatment, and at progression.
      Patients who discontinued treatment for any reason other than progression were required to
      follow the same schedule of assessments until progression, initiation of another treatment,
      death, or withdrawal of consent.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Date of randomisation to date of first tumour progression or death (this can range on average between 3 weeks and 32 weeks).</time_frame>
    <description>Progression-free survival, defined as the time from the date of randomisation to the date of first documented tumour progression (using RECIST 1.1) or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + AZD5363</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patient receive Once a week for three weeks - with one week off treatment</description>
    <arm_group_label>Paclitaxel + AZD5363</arm_group_label>
    <arm_group_label>Paclitaxel + Placebo</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5363</intervention_name>
    <description>Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.</description>
    <arm_group_label>Paclitaxel + AZD5363</arm_group_label>
    <other_name>Capivasertib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.</description>
    <arm_group_label>Paclitaxel + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent prior to admission to this study

          2. Women, age &gt; 18 years

          3. Histologically confirmed breast cancer

          4. Metastatic or locally recurrent disease; locally recurrent disease must not be
             amenable to resection with curative intent (patients who are considered suitable for
             surgical or ablative techniques following potential down-staging with study treatment
             are not eligible)

          5. Patient must have

               -  At least one lesion, not previously irradiated, that can be measured accurately
                  at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have
                  short axis ≥15mm) with CT, or magnetic resonance imaging (MRI) which is suitable
                  for accurate repeated measurements, OR

               -  lytic or mixed bone lesions in the absence of measurable disease as defined
                  above; patients with sclerotic/osteoblastic bone lesions only in the absence of
                  measurable disease are not eligible.

          6. Radiological or clinical evidence of recurrence or progression

          7. Triple-negative disease

          8. Formalin fixed paraffin embedded tumour sample from the primary or recurrent cancer
             must be available for central testing

          9. Patients must be able to swallow and retain oral medication

         10. Haematologic and biochemical indices within protocol specified ranges

         11. ECOG performance status 0-2

         12. Non-childbearing potential. If patient is of childbearing potential, she must have a
             negative serum pregnancy test and agree to use adequate contraception

         13. Willing and able to provide written informed consent

        Exclusion Criteria:

          1. Patients with confirm brain metastases or a history of primary central nervous system
             tumours or who have signs/symptoms attributable to brain metastases and have not been
             assessed with radiologic imaging to rule out the presence of brain metastases.

          2. Prior chemotherapy for metastatic breast cancer

          3. Radiotherapy with a wide field of radiation within 4 weeks before the first dose of
             study medication

          4. Prior treatment with PI3K inhibitors, AKT inhibitors or mTOR inhibitors

          5. Prior treatment with paclitaxel or docetaxel in the (neo)adjuvant setting within 12
             months from inclusion into this study

          6. Pre-existing sensory or motor polyneuropathy ≥ Grade 2 according to CTCAE

          7. Malabsorption syndrome or other condition that would interfere with enteral absorption

          8. Clinically significant pulmonary dysfunction

          9. Prolongation defined as a QTc interval &gt;470msecs or other significant abnormalities in
             rhythm, conduction or morphology of resting ECG including 2nd degree (Type II) or 3rd
             degree AV block or bradycardia (ventricular rate &lt;50 beats/min)

         10. Any factors that increase risk of QTc prolongation or risk of arrythmic events

         11. Experience of any of the following procedures or conditions in the preceding 6 months:
             coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction,
             angina pectoris, congestive heart failure NYHA Grade ≥2, or cardiac ejection fraction
             outside institutional range of normal or &lt;50%

         12. Clinically significant abnormalities of glucose metabolism

         13. Patients with proteinuria or creatine &gt;1.5xULN concurrent with creatinine clearance
             &lt;50mL/min

         14. Exposure to potent inhibitors or inducers or substrates of CYP3A4 or substrates of
             CYP2D6 within 2 weeks before the first dose of study treatment

         15. Concurrent treatment with other experimental drugs or participation in another
             clinical trial with any investigational drug within 30 days prior to study entry

         16. Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the study protocol.

         17. Detained persons or prisoners

         18. Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Schmid</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Mary University London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Turner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden Hospital NHS- Institute of Cancer Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre André-lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Prive Saint-Gregoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Oncology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pécs - Clinical Center Institute of Oncotherapy</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala County Hospital Szent Rafael</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Centre</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. I. Chiricuta Oncology Institute</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Nectarie SRL Oncologie Medical Center</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Oncology Euroclinic</name>
      <address>
        <city>Iași</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Betsi Cadwaladr University Health Board</name>
      <address>
        <city>Bangor</city>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital BCU Health Board NHS Wales</name>
      <address>
        <city>Bodelwyddan</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Kent Hospitals University NHS Foundation Trust</name>
      <address>
        <city>Canterbury</city>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHs Trust</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway NHS Foundation Trust</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHs Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barking, Havering and Redbridge University Hospitals NHS Trust</name>
      <address>
        <city>London</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lewisham and Greenwich NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust-Fulham</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone and Tunbridge Wells NHS Trust</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Southend</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Staffordshire NHS Trust</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Sutton</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abertawe Bro Margannwg University Health Board</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ysbyty Wrexham Maelor Hospital</name>
      <address>
        <city>Wrexham</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital NHS Foundation Trust</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol. 2020 Feb 10;38(5):423-433. doi: 10.1200/JCO.19.00368. Epub 2019 Dec 16.</citation>
    <PMID>31841354</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>AKT Inhibitor</keyword>
  <keyword>Advanced</keyword>
  <keyword>AZD5363</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>PAKT</keyword>
  <keyword>Capivasertib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

